中文

About Us

Arctic Vision is a China-based ophthalmic biotech focusing on
breakthrough therapies, with a leading portfolio covering
pre-clinical stage to commercial stage products.

Science & Pipeline

Pipeline Indication Commercial Rights Pre-clinical Phase I Phase II Phase III NDA/
Regulatory
Approval		 Marketed
锋脉*/
ARCATUS®
(ARVN001)		 Uveitis (Uveitic Macular Edema) Greater China,
South Korea, India,
ASEAN countries,
Australia, New Zealand
 
          
Diabetic Macular Edema
 
          
MPL® Myopia and Hyperopia Global
 
          
ARVN901 Corneal Endothelial Dysfunction Greater China, South Korea
 
          
ARVN005 Geographic Atrophy Globa
 
          
ARVN601 Glaucoma Global
 
          
IOL Series Cataract Global
 
          
ITEAR®
(ARVN701)		 Dry Eye Disease Greater China,
South Korea, ASEAN countries
 
          
ARVN602 & 603 Inherited Retinal Degeneration Global
 
          
ARVN8 Series Ophthalmic Healthcare Product Matrix Global
 
          
Defocus Lens Pediatric Myopia Control Global
 
          

News Center

  • Feb 12, 2026
    Arctic Vision Announces Deal to Integrate MDCO Technology's Ophthalmic Device Business to Form a Global Drug–Device Innovation Platform
    →
  • Jan 02, 2026
    Arctic Vision Announced TGA Approval of New Drug Application for ARCATUS® (ARVN001) to Treat Uveitic Macular Edema (UME) in Australia
    →
  • Jan 20, 2026
    Innovation is everywhere – Hong Kong Enterprise Innovation Project Selection and Recognition Conference came to a Successful Conclusion
    →
Investor Relations
 
We look forward to providing innovative and transformative technologies that meet             changing consumer needs and help ophthalmic patients and consumers see clearer, live better.
Global Cooperation
Through in-house research and development, co-development and in-licensing, we aim to bring innovative and transformative ophthalmic...
CLOSE